Dexcom Launches World’s First Generative AI Platform for Glucose Monitoring

Dexcom Launches World’s First Generative AI Platform for Glucose Monitoring

Facebook
Twitter
LinkedIn

Dexcom, Inc., a leader in glucose biosensing technology, on Tuesday announced the launch of its proprietary Generative AI platform, becoming the first continuous glucose monitor (CGM) manufacturer to integrate GenAI into its technology .

The new Dexcom GenAI platform analyzes individual health data patterns to identify connections between lifestyle choices and glucose levels, providing actionable insights for improved metabolic health .

Stelo, Dexcom’s over-the-counter glucose biosensor cleared by the FDA, is the first product to utilize the GenAI-enabled technology for weekly insights. An enhancement of Stelo’s Weekly Insights feature, which began rolling out this week, offers users more personalized tips, recommendations, and education on diet, exercise, and sleep within the Stelo app.

“The launch of our GenAI platform reinforces our long-standing reputation as the glucose biosensing leader,” said Jake Leach, executive vice president and chief operating officer at Dexcom, adding it would open the door for future advancements in the company’s product portfolio.

Dexcom built its GenAI platform using Google Cloud’s Vertex AI platform and Gemini models. Chris Sakalosky, vice president of Strategic Industries for Google Cloud, said by bringing the power of Google Cloud’s Vertex AI and Gemini to Dexcom’s technology, users will have more personalized insights.

Leach participated in a panel discussion on Health AI in 2030 at CES 2025 on January 8, 2025. The panel discussed how AI will revolutionize health care over the next five years .

Dexcom, founded in 1999, has pioneered glucose biosensing technology for over 25 years, providing tools for diabetes management and glucose tracking.